Background and Aims Over 4 million deaths from coronavirus disease (COVID)‐19 have been reported in the world. Several biomarkers have been identified that predict disease severity, but there is still a need to identify biomarkers for death risk in severe COVID‐19. We aim to define amongst the biomarkers already identified those which are mostly associated with increased death rate in patients with severe COVID‐19. Methods In this retrospective study conducted in three public hospitals linked to the Medical School of Ribeirão Preto, Brazil, patients with severe COVID‐19 were evaluated regarding biomarkers (neutrophil‐to‐lymphocyte ratio‐NLR, D‐dimer, fibrinogen) of death risk, obtained before administration of corticosteroids. Results Thirty‐nine (32.8%) of the 119 patients included (104 [87.4%] on mechanical ventilation) died during hospitalization. Non‐survivor group had higher median (range) NLR (12.63 [2.6‐115] vs 7.43 [0.43‐31.8]; P = .001), D‐dimer (2.17 [0.27‐20.00] vs 1.57 [0.28‐20.00]; P = .03), but lower fibrinogen (631 [353‐1078] vs 705 [407‐1200]; P = .02). The group with NLR ≥ 10 and D‐dimer ≥ 2 μg/mL had a higher death risk than the group with NLR < 10 and D‐dimer < 2 μg/mL (OR: 5.39; CI 95%: 1.5‐19.42; P = .01). Conclusion High NLR and D‐dimer, especially when combined, are predictors of death risk for patients with severe COVID‐19 and should be incorporated into their evaluation.
Objectives Evaluate the impact of ABO histo‐blood group type on COVID‐19 severity. Background ABO histo‐blood type has been associated with different outcomes in infectious diseases. It has also shown a higher proportion of type A patients with SARS‐CoV‐2. In this observational study, extracted from an ongoing clinical trial on the efficacy of convalescent plasma transfused in COVID‐19 patients, we describe the impact of ABO blood type on the risk of developing severe COVID‐19. Materials and Methods Seventy‐two consecutive patients (37 type A, 23 type O, 11 type B, 1 type AB) with severe (respiratory failure) COVID‐19 were included. Control group was composed of 160 individuals randomly selected from the same populational basis. Results Blood group A was overrepresented (51.39%) in the patient group in relation to the control group (30%), whereas blood group O was less represented (31.94%) in patient than in control group (48%). Odds ratio (A vs. O) was 2.581 (1.381–4.817), CI 95%; p = 0.004. Also, blood group A patients appeared to have more severe disease, given by the scores of the Sequential Organ Failure Assessment and Simplified Acute Physiologic Score 3 ( p = 0.036 and p = 0.058, respectively). Conclusion Histo‐blood type A is associated with a higher risk of developing severe COVID‐19 in relation to blood type O.
Background: Steroid-refractory acute graft-vs.-host disease (SR-aGVHD) is a complication of allogeneic hematopoietic stem cell transplantation with a dismal prognosis and for which there is no consensus-based second-line therapy. Ruxolitinib is not easily accessible in many countries. A possible therapy is the administration of mesenchymal stromal cells (MSCs). Methods: In this retrospective study, 52 patients with severe SR-aGVHD were treated with MSCs from umbilical cord (UC-MSCs) in nine institutions. Results: The median (range) age was 12.5 (0.3–65) years and the mean ± SD dose (×106/kg) was 4.73 ± 1.3 per infusion (median of four infusions). Overall (OR) and complete response (CR) rates on day 28 were 63.5% and 36.6%, respectively. Children (n = 35) had better OR (71.5% vs. 47.1%, p = 0.12), CR (48.6% vs. 11.8%, p = 0.03), overall survival (p = 0.0006), and relapse-free survival (p = 0.0014) than adults (n = 17). Acute adverse events (all of them mild or moderate) were detected in 32.7% of patients, with no significant difference in children and adult groups (p = 1.0). Conclusions: UC-MSCs are a feasible alternative therapy for SR-aGVHD, especially in children. The safety profile is favorable.
Introdução:A síndrome da secreção inapropriada do hormônio antidiurético (SIADH) consiste na incapacidade de supressão do hormônio antidiurético (ADH), comprometendo os mecanismos de excreção da água e concentração urinária. Possui como manifestações a hiponatremia e seus sintomas, sobretudo neurológicos. Há variadas causas que desencadeiam tal distúrbio, a se destacarem: distúrbios do sistema nervoso central, neoplasias malignas e drogas, dentre outros. Relato de Caso: Paciente feminina, 65 anos, hipertensa, apresentando manifestações clínicas e laboratoriais correspondentes à hiponatremia. O fato ocorreu em duas ocasiões em vigência de medicação fitoterápica para tratamento de osteoartrite. Discussão: A hiponatremia relacionada às drogas pode ser provocada pelo efeito direto do medicamento ou por desencadear SIADH. As manifestações clínicas apresentadas poderiam ter sido atribuídas a um quadro psiquiátri-co, o que poderia ter desfecho grave, caso não diagnosticada corretamente. A associação de um fitoterápico à SIADH pôde ser confirmada após novo episódio de hiponatremia relacionado à reintrodução do Harpagophytum procumbers. Nossa revisão da literatura não encontrou este fitoterápico associado à SIADH, até o momento. Conclusão: SIADH pode ser ocasionada por medicamento fitoterápico doravante descrita sua associação na literatura.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.